PROCEPT BioRobotics Corporation (PRCT)
NEUTRALFundamental
39
Price
$21.36
Market Cap
$1.20B
Part 1 · What the company is worth
Overview
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$337M
Trailing 12 months (through 6/30/2026)
Net Income
$-110M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-58M
Total Equity
$366M
Total Liabilities
$142M
Current Ratio
6.55
Interest Coverage
32.88
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$21.64
Current Price
$21.36
Margin of Safety
+1.3%
Fair Value Range
$20.55 - $22.72
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-26.1%
P/B Ratio
3.58
P/FCF
-
Gross Margin
64.2%
ROIC
-21.7%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-21.7%
WACC
9.3%
ROIC − WACC
-31.0 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (8)
- EPS shows upward trend
- Gross Margin 64.2%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 109.0%
- Analyst Consensus 57% Buy
Failed (12)
- Price CAGR -2.82%
- ROIC -21.7%
- P/B Ratio 3.58
- Operating Margin -33.9%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -30.6%
- Earnings Surprise avg -12.6%
- Share Dilution 6.4%
- Net Margin Trend -32.5% vs -30.6%
- Piotroski F-Score 3/9
Unavailable (7)
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Larry L. Wood | President, CEO & Director | 59 |
| Mr. Kevin Waters | Executive VP & CFO | 48 |
| Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corporate Secretary | 46 |
| Mr. Christofer Christoforou | Executive Vice President of Operations | 55 |
| Mr. Barry Templin | Executive VP & CTO | - |
| Mr. Matthew James Bacso C.F.A. | Vice President of Investor Relations | - |
| Ms. Pooja Sharma Rao | Executive VP and Chief Strategy & Marketing Officer | - |
| Ms. Stacey L. Porter | Executive VP & Chief People Officer | 50 |
| Mr. Bijesh Chandran | Executive Vice President of Regulatory Affairs & Quality Assurance | - |
| Mr. Stephen J. McGill | Senior VP & GM of International | 63 |
Audit Risk
6
Board Risk
5
Compensation Risk
10
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for PRCT, sourced from Markets Gazette.